Evidence map›Paper›PMID 41942871›Full record

ArticleMolecular medicine (Cambridge, Mass.)2026

Functional impact of the eIF6 N106S mutation on ribosome biogenesis in wild type and Shwachman-Diamond syndrome cells.

Alexis Bertrand, Sarah Le Page, Vithura Pirabakaran, Laëtitia Kermasson, Erika Brunet, Jean Donadieu, Pierre-Emmanuel Gleizes, Marie-Françoise O'Donohue, Patrick Revy

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexis BertrandLaboratory of Genome Dynamics in Human Diseases, Equipe Labellisée Ligue 2026, INSERM UMR 1163, Imagine Institute, Paris, France. alexis.bertrand92@gmail.com.
Sarah Le PageMolecular, Cellular and Developmental biology department (MCD), Centre de Biologie Intégrative (CBI), Université de Toulouse, CNRS, Toulouse, France.
Vithura PirabakaranLaboratory of Genome Dynamics in Human Diseases, Equipe Labellisée Ligue 2026, INSERM UMR 1163, Imagine Institute, Paris, France.
Laëtitia KermassonLaboratory of Genome Dynamics in Human Diseases, Equipe Labellisée Ligue 2026, INSERM UMR 1163, Imagine Institute, Paris, France.
Erika BrunetLaboratory of Genome Dynamics in Human Diseases, Equipe Labellisée Ligue 2026, INSERM UMR 1163, Imagine Institute, Paris, France.
Jean DonadieuHôpital Trousseau, Paris, France.
Pierre-Emmanuel GleizesMolecular, Cellular and Developmental biology department (MCD), Centre de Biologie Intégrative (CBI), Université de Toulouse, CNRS, Toulouse, France.
Marie-Françoise O'DonohueMolecular, Cellular and Developmental biology department (MCD), Centre de Biologie Intégrative (CBI), Université de Toulouse, CNRS, Toulouse, France.
Patrick RevyLaboratory of Genome Dynamics in Human Diseases, Equipe Labellisée Ligue 2026, INSERM UMR 1163, Imagine Institute, Paris, France. patrick.revy@inserm.fr.

Funding

Ligue Contre le Cancer LIGUE 2023
6 · The paper itself

Abstract

backgroundEukaryotic initiation factor 6 (eIF6) is an essential regulator of ribosome biogenesis that prevents the premature association of the 60S and 40S ribosomal subunits. eIF6 eviction from nascent 60S particles, mediated by the ribosome biogenesis factors SBDS and EFL1, is required for the formation of translationally competent 80S ribosomes. SBDS and EFL1 deficiencies cause Shwachman-Diamond syndrome (SDS), a ribosomopathy mainly characterized by exocrine pancreatic insufficiency, bone marrow failure and a predisposition to hematological malignancies. Somatic EIF6 mutations that reduce the amount of eIF6 (e.g., nonsense mutation, deletion) or its ability to bind to the 60S subunit (e.g., N106S missense mutation) are frequently found in hematopoietic cells of SDS individuals. These somatic EIF6 mutations represent indirect somatic genetic rescue (SGR) in the context of SDS, as they increase cellular fitness to cause clonal expansion and are associated with clinical improvement in some cases. However, the functional consequences of these eIF6 mutations in human SDS cells have never been reported to date.

methodsAs fibroblasts from individuals with SDS carrying biallelic pathogenic variants in either SBDS or EFL1 exhibit impaired ribosome production and reduced translation, we employed these cells, in addition to fibroblasts from a healthy donor, as a cellular model to analyze the impact of the EIF6 N106S mutation, which was introduced by CRISPR/Cas9-mediated genome editing. The assessment of eIF6 localization, ribosome biogenesis, ribosomal RNA (rRNA) processing, global protein synthesis, cellular fitness, and p53 pathway activation was conducted in these cells.

resultsEndogenous expression of the eIF6 N106S mutant altered the subcellular distribution of eIF6 and induced pronounced defects, including impaired ribosomal RNA 3′-ETS processing, reduced availability of mature 60S subunits, and accumulation of halfmer polysomes. These alterations were associated with reduced cellular fitness in both healthy donor and SDS fibroblasts. In the context of SBDS deficiency, the N106S mutation partially alleviated aberrant retention of eIF6 on the 60S subunit but failed to restore global translation or confer a proliferative advantage.

conclusionsOur study reveals that the eIF6 N106S mutation uncouples partial correction of eIF6–60S dissociation from proper rRNA biogenesis and cellular fitness. These findings reveal intrinsic limits to altering eIF6–60S interactions without disrupting ribosome biogenesis. Furthermore, these results emphasize that therapeutic strategies targeting the eIF6–60S interaction must carefully balance rescue of ribosomal stress against disruption of ribosome biogenesis, particularly in disease contexts such as Shwachman-Diamond syndrome.

Indexed as

Bone Marrow DiseasesEukaryotic Initiation FactorsExocrine Pancreatic InsufficiencyLipomatosisMutationPeptide Initiation FactorsRibosomesShwachman-Diamond SyndromeFibroblastsHumansPeptide Elongation FactorsProteinsRibonucleoprotein, U5 Small NuclearRibosome Subunits, Large, EukaryoticEFL1 protein, humaneIF-6EIF6 protein, humanEukaryotic Initiation FactorsPeptide Elongation FactorsPeptide Initiation FactorsProteinsRibonucleoprotein, U5 Small NuclearSBDS protein, humaneIF6Ribosomal RNA biogenesisRibosomeShwachman-Diamond syndrome

Identifiers

PMID41942871
PMCPMC13235181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.